Recently, pharmaceutical and medical device giant Johnson & Johnson (JNJ) has become the focus of market attention, as its market capitalization surpassed the $500 billion mark for the first time. This milestone was achieved on Wednesday, when its stock price rose 0.4% to close at $207.56. This gain marked the stock’s 13th consecutive day of closing higher, setting the company’s longest-ever winning streak. Throughout November, Johnson & Johnson’s stock price accumulated a gain of 9.9%, poised to record its best monthly performance since April 2020. For the year to date, its stock price has risen by 44%, on track for its best annual performance since 1995, successfully reversing the consecutive declines seen in 2023 and early 2024.
The strong performance of Johnson & Johnson, as well as the entire pharmaceutical sector, is also closely related to broader capital flows. The market is currently witnessing a rotation away from high-risk areas and highly valued artificial intelligence stocks toward more defensive sectors. The healthcare sector has benefited as a result, with the S&P 500 healthcare sector rising 9.7% this month, set to achieve its largest monthly gain since April 2020.
The strong bullish sentiment on Wall Street primarily stems from investors’ confidence in Johnson & Johnson’s strategy to address the revenue gap from its core products. The company’s psoriasis treatment drug, Stelara, is facing challenges due to patent expiration, raising market concerns about a subsequent decline in its sales. To fill this potential revenue gap, Johnson & Johnson is actively enriching its product pipeline through new product deployments and strategic acquisitions. Earlier this year, the company acquired neuroscience drug developer Intra-Cellular Therapies Inc. for approximately $14.6 billion, aiming to gain access to a new drug for treating major depressive disorder. Shortly after, last week, it agreed to acquire cancer treatment biotechnology company Halda Therapeutics for over $3 billion. These moves clearly demonstrate the company’s determination to maintain its business growth momentum.
Analysis generally believes that Johnson & Johnson is known for its steady management strategy, consistently exceeding market expectations in performance, and poses relatively lower risks compared to many peers. This “no-surprise” stable performance makes it more attractive in the current market environment. The company recently also raised its full-year sales forecast and plans to spin off its slower-growing orthopedics business within the next 18 to 24 months, further optimizing its business structure. Although Wall Street’s consensus price target for the next 12 months is approximately $205, roughly in line with the current closing price, more than half of the tracking analysts still rate the stock a “Buy.” Scotiabank analyst Louise Chen gave Johnson & Johnson the highest price target and listed it as a “Top Pick,” stating in her report: “Excellent execution is making the company’s fundamental growth trajectory increasingly evident.”
